The role of post-translational modifications in acute and chronic cardiovascular disease

Proteomics - Clinical Applications

Volumn 8, Issue 7-8, 2014, Pages 506-521

  Smith, Lauren E ^a   White, Melanie Y ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Ischemia; PTM; PTM crosstalk; Reperfusion injury; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; INSULIN; PROTEOME; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TRANSCRIPTOME;

ACUTE DISEASE; ACYLATION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC DISEASE; COMORBIDITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC RISK; GENOME ANALYSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; PROTEOMICS;

ACUTE DISEASE; ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS;

EID: 84906058450     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400052     Document Type: Review

References (169)

1. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J. et al., Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129, e28-e292.
2. Nichols, C. G., Singh, G. K., Grange, D. K., KATP channels and cardiovascular disease: suddenly a syndrome. Circ. Res. 2013, 112, 1059-1072.
3. Roberts, R., Stewart, A. F. R., The genetics of coronary artery disease. Curr. Opin. Cardiol. 2012, 27, 221-227.
4. Cappola, T. P., Matkovich, S. J., Wang, W., van Booven, D. et al., Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc. Natl. Acad. Sci. USA 2011, 108, 2456-2461.
5. Matkovich, S. J., Van Booven, D. J., Hindes, A., Kang, M. Y. et al., Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J. Clin. Invest. 2010, 120, 280-289.
6. Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S. et al., A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316, 1491-1493.
7. McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A. et al., A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316, 1488-1491.
8. Barroso, I., Gurnell, M., Crowley, V. E., Agostini, M. et al., Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402, 880-883.
9. Siffert, W., Rosskopf, D., Siffert, G., Busch, S. et al., Association of a human G-protein beta3 subunit variant with hypertension. Nat. Genet. 1998, 18, 45-48.
10. Wang, Q., Shen, J. X., Splawski, I., Atkinson, D. et al., SCN5A mutations associated with an inherited cardiac-arrhythmia, long QT syndrome. Cell 1995, 80, 805-811.
11. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M. et al., A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80, 795-803.
12. Morales, A., Hershberger, R. E., Genetic evaluation of dilated cardiomyopathy. Curr. Cardiol. Rep. 2013, 15, 375.
13. Cahill, T. J., Ashrafian, H., Watkins, H., Genetic cardiomyopathies causing heart failure. Circ. Res. 2013, 113, 660-675.
14. Dolk, H., Loane, M., Garne, E., A European Surveillance of Congenital Anomalies (EUROCAT) Working Group, congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation 2011, 123, 841-849.
15. Churko, J. M., Mantalas, G. L., Snyder, M. P., Wu, J. C., Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circ. Res. 2013, 112, 1613-1623.
16. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., Wold, B., Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008, 5, 621-628.
17. Nagalakshmi, U., Wang, Z., Waern, K., Shou, C. et al., The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 2008, 320, 1344-1349.
18. Lister, R., O'Malley, R. C., Tonti-Filippini, J., Gregory, B. D. et al., Highly integrated single-base resolution maps of the epigenome in arabidopsis. Cell 2008, 133, 523-536.
19. Sultan, M., Schulz, M. H., Richard, H., Magen, A. et al., A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321, 956-960.
20. Lee, J.-H., Gao, C., Peng, G., Greer, C. et al., Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ. Res. 2011, 109, 1332-1341.
21. Gallego-Delgado, J., Connolly, S. B., Lázaro, A., Sadlier, D. et al., Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies. Hypertens. Res. 2009, 32, 347-357.
22. de Godoy, L., Olsen, J. V., Cox, J., Nielsen, M. et al., Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast. Nature 2008, 455, 1251-1254.
23. Kislinger, T., Cox, B., Kannan, A., Chung, C. et al., Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006, 125, 173-186.
24. Lundberg, E., Fagerberg, L., Klevebring, D., Matic, I. et al., Defining the transcriptome and proteome in three functionally different human cell lines. Mol. Syst. Biol. 2010, 6, 450.
25. Libby, P., Ridker, P. M., Maseri, A., Inflammation and atherosclerosis. Circulation 2002, 105, 1135-1143.
26. Sanguinetti, M. C., Jiang, C., Curran, M. E., Keating, M. T., A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81, 299-307.
27. Weber, K. T., Brilla, C. G., Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83, 1849-1865.
28. van Eyk, J. E., Powers, F., Law, W., Larue, C. et al., Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ. Res. 1998, 82, 261-271.
29. Murphy, E., Steenbergen, C., Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 2008, 88, 581-609.
30. Zhang, P., Kirk, J. A., Remedios, dos, C., Ji, W. et al., Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation 2012, 126, 1828-1837.
31. Jacquet, S., Yin, X., Sicard, P., Clark, J. et al., Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol. Cell. Proteomics 2009, 8, 2687-2699.
32. Cordwell, S. J., Edwards, A. V. G., Liddy, K. A., Moshkanbaryans, L. et al., Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury. J. Proteome Res. 2012, 11, 2114-2126.
33. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotech. 2011, 29, 635-643.
34. Cordwell, S. J., White, M. Y., Targeted proteomics for determining phosphorylation site-specific associations in cardiovascular disease. Circulation 2012, 126, 1803-1807.
35. White, M. Y., Cordwell, S. J., McCarron, H. C. K., Tchen, A. S. et al., Modifications of myosin-regulatory light chain correlate with function of stunned myocardium. J. Mol. Cell. Cardiol. 2003, 35, 833-840.
36. White, M. Y., Hambly, B. D., Jeremy, R. W., Cordwell, S. J., Ischemia-specific phosphorylation and myofilament translocation of heat shock protein 27 precedes alpha B-crystallin and occurs independently of reactive oxygen species in rabbit myocardium. J. Mol. Cell. Cardiol. 2006, 40, 761-774.
37. Gupta, M. K., Gulick, J., James, J., Osinska, H. et al., Functional dissection of myosin binding protein C phosphorylation. J. Mol. Cell. Cardiol. 2013, 64, 39-50.
38. Flashman, E., Cardiac myosin binding protein C: its role in physiology and disease. Circ. Res. 2004, 94, 1279-1289.
39. Barefield, D., Sadayappan, S., Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J. Mol. Cell. Cardiol. 2010, 48, 866-875.
40. Sadayappan, S., Gulick, J., Osinska, H., Barefield, D. et al., A critical function for Ser-282 in cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res. 2011, 109, 141-150.
41. Decker, R. S., Decker, M. L., Kulikovskaya, I., Nakamura, S. et al., Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation 2005, 111, 906-912.
42. Colyer, J., Phosphorylation states of phospholamban. Ann. N. Y. Acad. Sci. 1998, 853, 79-91.
43. Schoutsen, B., Blom, J. J., Verdouw, P. D., Lamers, J. M., Calcium transport and phospholamban in sarcoplasmic reticulum of ischemic myocardium. J. Mol. Cell. Cardiol. 1989, 21, 719-727.
44. Said, M., Vittone, L., Mundina-Weilenmann, C., Ferrero, P. et al., Role of dual-site phospholamban phosphorylation in the stunned heart: insights from phospholamban site-specific mutants. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H1198-H1205.
45. Valverde, C. A., Mundina-Weilenmann, C., Reyes, M., Kranias, E. G. et al., Phospholamban phosphorylation sites enhance the recovery of intracellular Ca2+ after perfusion arrest in isolated, perfused mouse heart. Cardiovasc. Res. 2006, 70, 335-345.
46. Edwards, A. V. G., Cordwell, S. J., White, M. Y., Phosphoproteomic profiling of the myocyte. Circ. Cardiovasc. Genet. 2011, 4, 575.
47. Armstrong, S. C., Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc. Res. 2004, 61, 427-436.
48. Juhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S. et al., Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 2004, 113, 1535-1549.
49. Tsang, A., Hausenloy, D. J., Mocanu, M. M., Yellon, D. M., Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res. 2004, 95, 230-232.
50. Mozaffari, M. S., Liu, J. Y., Schaffer, S. W., Effect of pressure overload on cardioprotection via PI3K-Akt: comparison of postconditioning, insulin, and pressure unloading. Am. J. Hypertens. 2010, 23, 668-674.
51. Yang, X., Liu, Y., Yang, X.-M., Hu, F. et al., Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity. Basic Res. Cardiol. 2011, 106, 421-430.
52. Li, D. Y., Tao, L., Liu, H., Christopher, T. A. et al., Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 2006, 11, 923-930.
53. Reid, E. A., Kristo, G., Yoshimura, Y., Ballard-Croft, C. et al., In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H2253-H2259.
54. Kim, M., Hunter, R. W., Garcia-Menendez, L., Gong, G. et al., Mutation in the γ2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ. Res. 2014, 114, 966-975.
55. Gao, X., Lin, B., Sadayappan, S., Patel, T. B., Interactions between the regulatory subunit of type I protein kinase A and p90 ribosomal S6 kinase1 regulate cardiomyocyte apoptosis. Mol. Pharmacol. 2013, 85, 357-367.
56. Salas, M. A., Valverde, C. A., Sanchez, G., Said, M. et al., The signaling pathway of CaMKII-mediated apoptosis and necrosis in the ischemia/reperfusion injury. J. Mol. Cell. Cardiol. 2010, 48, 1298-1306.
57. Ling, H., Gray, C. B. B., Zambon, A. C., Grimm, M. et al., Ca2+/calmodulin-dependent protein kinase II δ mediates myocardial ischemia/reperfusion injury through nuclear factor-κB. Circ. Res. 2013, 112, 935-944.
58. Xuan, Y., Tang, X., Banerjee, S., Takano, H. et al., Nuclear factor-κB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 1999, 84, 1095-1109.
59. Lima, V. V., Rigsby, C. S., Hardy, D. M., Webb, R. C., Tostes, R. C., O-GlcNAcylation: a novel post-translational mechanism to alter vascular cellular signaling in health and disease: focus on hypertension. J. Am. Soc. Hypertens. 2009, 3, 374-387.
60. Hart, G. W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011, 80, 825-858.
61. Zachara, N. E., Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J. Biol. Chem. 2004, 279, 30133-30142.
62. Copeland, R. J., Bullen, J. W., Hart, G. W., Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E17-E28.
63. Clark, R. J., McDonough, P. M., Swanson, E., Trost, S. U. et al., Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem. 2003, 278, 44230-44237.
64. Wells, L., Vosseller, K., Hart, G. W., Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001, 291, 2376-2378.
65. Dias, W. B., Hart, G. W., O-GlcNAc modification in diabetes and Alzheimer's disease. Mol. Biosyst. 2007, 3, 766-772.
66. Wang, Z., Gucek, M., Hart, G. W., Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. USA 2008, 105, 13793-13798.
67. McLarty, J. L., Marsh, S. A., Chatham, J. C., Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci. 2013, 92, 621-627.
68. Erickson, J. R., Pereira, L., Wang, L., Han, G. et al., Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013, 502, 372-376.
69. Yokoe, S., Asahi, M., Takeda, T., Otsu, K. et al., Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology 2010, 20, 1217-1226.
70. Morris, G. L., Cheng, H. C., Colyer, J., Wang, J. H., Phospholamban regulation of cardiac sarcoplasmic reticulum (Ca(2+)-Mg2+)-ATPase. Mechanism of regulation and site of monoclonal antibody interaction. J. Biol. Chem. 1991, 266, 11270-11275.
71. Ramirez-Correa, G. A., Jin, W., Wang, Z., Zhong, X. et al., O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. Circ. Res. 2008, 103, 1354-1358.
72. Wang, Z., Pandey, A., Hart, G. W., Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol. Cell. Proteomics 2007, 6, 1365-1379.
73. Meng, T.-C., Fukada, T., Tonks, N. K., Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell. 2002, 9, 387-399.
74. Thomas, S. R., Witting, P. K., Drummond, G. R., Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2008, 10, 1713-1765.
75. Paulech, J., Solis, N., Edwards, A. V. G., Puckeridge, M. et al., Large-scale capture of peptides containing reversibly oxidized cysteines by thiol-disulfide exchange applied to the myocardial redox proteome. Anal. Chem. 2013, 85, 3774-3780.
76. Sena, L. A., Chandel, N. S., Physiological roles of mitochondrial reactive oxygen species. Mol. Cell. 2012, 48, 158-167.
77. Canton, M., Neverova, I., Menabò, R., Van Eyk, J., Di Lisa, F., Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H870-H877.
78. Canton, M., Skyschally, A., Menabo, R., Boengler, K. et al., Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur. Heart J. 2006, 27, 875-881.
79. Canton, M., Menazza, S., Sheeran, F. L., Polverino de Laureto, P. et al., Oxidation of myofibrillar proteins in human heart failure. J. Am. Coll. Cardiol. 2011, 57, 300-309.
80. Erwin, P. A., Lin, A. J., Golan, D. E., Michel, T., Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 2005, 280, 19888-19894.
81. Burgoyne, J. R., Haeussler, D. J., Kumar, V., Ji, Y. et al., Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis. FASEB J. 2012, 26, 832-841.
82. Kwak, Y.-D., Ma, T., Diao, S., Zhang, X. et al., NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 2010, 5, 49-1641.
83. Azad, N., Vallyathan, V., Wang, L., Tantishaiyakul, V. et al., S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J. Biol. Chem. 2006, 281, 34124-34134.
84. Kim, S., Wing, S. S., Ponka, P., S-nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway. Mol. Cell. Biol. 2004, 24, 330-337.
85. Murray, C. I., Kane, L. A., Uhrigshardt, H., Wang, S.-B., van Eyk, J. E., Site-mapping of in vitro S-nitrosation in cardiac mitochondria: implications for cardioprotection. Mol. Cell. Proteomics 2011, 10, M110.004721.
86. Murray, C. I., Uhrigshardt, H., O'Meally, R. N., Cole, R. N., van Eyk, J. E., Identification and quantification of S-nitrosylation by cysteine reactive tandem mass tag switch assay. Mol. Cell. Proteomics 2012, 11, M111.013441.
87. Behring, J. B., Kumar, V., Whelan, S. A., Chauhan, P. et al., Does reversible cysteine oxidation link the Western diet to cardiac dysfunction? FASEB J. 2014, 28, 1975-1987.
88. Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J. H. et al., Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors binding-proteins. J. Biol. Chem. 1994, 269, 9889-9897.
89. Ahmed, N., Advanced glycation end products-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67, 3-21.
90. Brownlee, M., Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 1995, 46, 223-234.
91. Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V. et al., A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 2003, 92, 785-792.
92. Manigrasso, M. B., Juranek, J., Ramasamy, R., Schmidt, A. M., Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol. Metab. 2014, 25, 15-22.
93. Singh, R., Barden, A., Mori, T., Beilin, L., Advanced glycation end-products: a review. Diabetologia 2001, 44, 129-146.
94. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 2010, 107, 1058-1070.
95. McCance, D. R., Dyer, D. G., Dunn, J. A., Bailie, K. E. et al., Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993, 91, 2470-2478.
96. Paul, R. G., Bailey, A. J., The effect of advanced glycation end-product formation upon cell-matrix interactions. Int. J. Biochem. Cell Biol. 1999, 31, 653-660.
97. Dyer, D. G., Dunn, J. A., Thorpe, S. R., Bailie, K. E. et al., Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 1993, 91, 2463-2469.
98. Goldin, A., Beckman, J. A., Schmidt, A. M., Creager, M. A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114, 597-605.
99. Sims, T. J., Rasmussen, L. M., Oxlund, H., Bailey, A. J., The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996, 39, 946-951.
100. Corman, B., Duriez, M., Poitevin, P., Heudes, D. et al., Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 1998, 95, 1301-1306.
101. Bodiga, V. L., Eda, S. R., Bodiga, S., Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail. Rev. 2014, 19, 49-63.
102. Smit, A. J., Lutgers, H. L., The clinical relevance of advanced glycation end products (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr. Med. Chem. 2004, 11, 2767-2784.
103. Tanaka, S., Avigad, G., Brodsky, B., Eikenberry, E. F., Glycation induces expansion of the molecular packing of collagen. J. Mol. Biol. 1988, 203, 495-505.
104. Kass, D. A., Shapiro, E. P., Kawaguchi, M., Capriotti, A. R. et al., Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104, 1464-1470.
105. Monnier, V. M., Glomb, M., Elgawish, A., Sell, D. R., The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996, 45(Suppl 3), S67-S72.
106. Haitoglou, C. S., Tsilibary, E. C., Brownlee, M., Charonis, A. S., Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem. 1992, 267, 12404-12407.
107. Brownlee, M., Vlassara, H., Cerami, A., Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985, 34, 938-941.
108. Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F. et al., Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 1995, 96, 1395-1403.
109. Schmidt, A. M., Hasu, M., Popov, D., Zhang, J. H. et al., Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. USA 1994, 91, 8807-8811.
110. Vlassara, H., Advanced glycation end-products and atherosclerosis. Ann. Med. 1996, 28, 419-426.
111. Wautier, M. P., Chappey, O., Corda, S., Stern, D. M. et al., Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E685-E694.
112. Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O. et al., Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272, 17810-17814.
113. Taguchi, A., Blood, D. C., del Toro, G., Canet, A. et al., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405, 354-360.
114. Huttunen, H. J., Fages, C., Rauvala, H., Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274, 19919-19924.
115. Schiekofer, S., Andrassy, M., Chen, J., Rudofsky, G. et al., Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor κB in PBMCs. Diabetes 2003, 52, 621-633.
116. Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K. et al., Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57, 2461-2469.
117. Ma, H., Li, S. Y., Xu, P., Babcock, S. A. et al., Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J. Cell. Mol. Med. 2009, 13, 1751-1764.
118. Bidasee, K. R., Nallani, K., Yu, Y., Cocklin, R. R. et al., Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 2003, 52, 1825-1836.
119. Bidasee, K. R., Zhang, Y., Shao, C. H., Wang, M. et al., Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 2004, 53, 463-473.
120. Pavlovic, D., Fuller, W., Shattock, M. J., Novel regulation of cardiac Na pump via phospholemman. J. Mol. Cell. Cardiol. 2013, 61, 83-93.
121. Fuller, W., Tulloch, L. B., Shattock, M. J., Calaghan, S. C. et al., Regulation of the cardiac sodium pump. Cell. Mol. Life Sci. 2013, 70, 1357-1380.
122. Sheldon, C., Church, J., Na+/H+ exchange: molecular regulation to therapeutic development. Clin. Invest. Med. 2002, 25, 229-232.
123. Zhao, Z. Q., Corvera, J. S., Halkos, M. E., Kerendi, F. et al., Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H579-H588.
124. Gomez, L., Paillard, M., Thibault, H., Derumeaux, G., Ovize, M., Inhibition of GSK3β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008, 117, 2761-2768.
125. Di Lisa, F., Menabò, R., Canton, M., Barile, M., Bernardi, P., Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J. Biol. Chem. 2001, 276, 2571-2575.
126. Griffiths, E., Halestrap, A., Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem. J. 1995, 307(Pt 1), 93-98.
127. Yin, X., Zheng, Y., Zhai, X., Zhao, X., Cai, L., Diabetic inhibition of preconditioning- and postconditioning-mediated myocardial protection against ischemia/reperfusion injury. Exp. Diabetes Res. 2012, 2012, 198048.
128. Gustafsson, A. B., Gottlieb, R. A., Heart mitochondria: gates of life and death. Cardiovasc. Res. 2008, 77, 334-343.
129. Penna, C., Mancardi, D., Rastaldo, R., Pagliaro, P., Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim. Biophys. Acta 2009, 1787, 781-793.
130. Cohen, M. V., Yang, X.-M., Downey, J. M., Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res. Cardiol. 2008, 103, 464-471.
131. Yang, X.-M., Proctor, J. B., Cui, L., Krieg, T. et al., Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J. Am. Coll. Cardiol. 2004, 44, 1103-1110.
132. Tsang, A., Hausenloy, D. J., Yellon, D. M., Myocardial postconditioning: reperfusion injury revisited. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2-H7.
133. Hausenloy, D. J., Lecour, S., Yellon, D. M., Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid. Redox Signal. 2011, 14, 893-907.
134. Bell, R., Yellon, D., Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J. Mol. Cell. Cardiol. 2003, 35, 185-193.
135. Tong, T., Chen, W., Steenbergen, C., Murphy, E., Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ. Res. 2000, 87, 309-315.
136. Perrelli, M.-G., Tullio, F., Angotti, C., Cerra, M. C. et al., Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial K(ATP) channels and ROS signalling. Pflugers Arch. Eur. J. Physiol. 2013, 465, 1031-1040.
137. Jonassen, A. K., Sack, M. N., Mjøs, O. D., Yellon, D. M., Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70S6 kinase cell-survival signaling. Circ. Res. 2001, 89, 1191-1198.
138. Javadov, S. A., Clarke, S., Das, M., Griffiths, E. J. et al., Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J. Physiol. 2003, 549, 513-524.
139. Miura, T., Miki, T., GSK-3β, a therapeutic target for cardiomyocyte protection. Circ. J. 2009, 73, 1184-1192.
140. Lecour, S., Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J. Mol. Cell. Cardiol. 2009, 47, 32-40.
141. Cunningham, D. A., Dunn, M. J., Yacoub, M. H., Rose, M. L., Local production of cytokines in the human cardiac allograft. A sequential study. Transplantation 1994, 57, 1333-1337.
142. Steenbergen, C., Afshari, C., Petranka, J., Collins, J. et al., Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am. J. Physiol. Heart Circ. Physiol. 2003, 284, H268-H276.
143. Jang, W., Kim, H., Park, K., Park, Y. et al., Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid. Proteomics 2004, 4, 3383-3393.
144. Maekawa, N., Wada, H., Kanda, T., Niwa, T. et al., Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J. Am. Coll. Cardiol. 2002, 39, 1229-1235.
145. Negoro, S., Kunisada, K., Fujio, Y., Funamoto, M. et al., Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001, 104, 979-981.
146. Stephanou, A., Brar, B. K., Knight, R. A., Latchman, D. S., Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 2000, 7, 329-330.
147. Freixa, X., Bellera, N., Ortiz-Perez, J. T., Jimenez, M. et al., Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur. Heart J. 2012, 33, 103-112.
148. Laskey, W. K., Yoon, S., Calzada, N., Ricciardi, M. J., Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter. Cardiovasc. Interv. 2008, 72, 212-220.
149. Lonborg, J., Kelbaek, H., Vejlstrup, N., Jorgensen, E. et al., Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ. Cardiovasc. Interv. 2010, 3, 34-41.
150. Sorensson, P., Saleh, N., Bouvier, F., Bohm, F. et al., Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 2010, 96, 1710-1715.
151. Staat, P., Rioufol, G., Piot, C., Cottin, Y. et al., Postconditioning the human heart. Circulation 2005, 112, 2143-2148.
152. Tarantini, G., Favaretto, E., Marra, M. P., Frigo, A. C. et al., Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int. J. Cardiol. 2012, 162, 33-38.
153. Thuny, F., Lairez, O., Roubille, F., Mewton, N. et al., Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2012, 59, 2175-2181.
154. Xue, F., Yang, X., Zhang, B., Zhao, C. et al., Postconditioning the human heart in percutaneous coronary intervention. Clin. Cardiol. 2010, 33, 439-444.
155. Hahn, J. Y., Song, Y. B., Kim, E. K., Yu, C. W. et al., Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation 2013, 128, 1889-1896.
156. Downey, J. M., Cohen, M. V., Why do we still not have cardioprotective drugs? Circ. J. 2009, 73, 1171-1177.
157. Przyklenk, K., Efficacy of cardioprotective "conditioning" strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging 2011, 28, 331-343.
158. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998, 339, 229-234.
159. Laakso, M., Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48, 937-942.
160. Brener, S. J., Mehran, R., Dressler, O., Cristea, E., Stone, G. W., Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am. J. Cardiol. 2012, 109, 1111-1116.
161. Carson, J. L., Scholz, P. M., Chen, A. Y., Peterson, E. D. et al., Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J. Am. Coll. Cardiol. 2002, 40, 418-423.
162. Cohen, Y., Raz, I., Merin, G., Mozes, B., Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am. J. Cardiol. 1998, 81, 7-11.
163. Luciani, N., Nasso, G., Gaudino, M., Abbate, A. et al., Coronary artery bypass grafting in type II diabetic patients: a comparison between insulin-dependent and non-insulin-dependent patients at short- and mid-term follow-up. Ann. Thorac. Surg. 2003, 76, 1149-1154.
164. Szabo, Z., Hakanson, E., Svedjeholm, R., Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann. Thorac. Surg. 2002, 74, 712-719.
165. Anderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A. et al., Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol. 2009, 54, 1891-1898.
166. Sasso, F. C., Torella, D., Carbonara, O., Ellison, G. M. et al., Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J. Am. Coll. Cardiol. 2005, 46, 827-834.
167. Sivaraman, V., Hausenloy, D. J., Wynne, A. M., Yellon, D. M., Preconditioning the diabetic human myocardium. J. Cell. Mol. Med. 2010, 14, 1740-1746.
168. Rolo, A. P., Palmeira, C. M., Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 2006, 212, 167-178.
169. Ansley, D. M., Wang, B., Oxidative stress and myocardial injury in the diabetic heart. J. Pathol. 2012, 229, 232-241.